InsightfulValue
← Home

Gilead Sciences
Gilead Sciences

Pharma / Pharma


πŸ”§ Tools

βœ… Due Diligence
🧩 Revenue Segmentation by Product

Switch to Location
Fiscal year Segment Value
2024 Veklury 1.8B
2024 Products, Other HIV 19.61B
2024 Other Products, Total Other product sales 889M
2024 Trodelvy 1.32B
2024 Cell Therapy Products, Total Cell Therapy Product Sales 2.38B
2023 Hepatitis B Virus / Hepatitis Delta Virus Product 1.02B
2023 Veklury 2.18B
2023 Products, Other HIV 18.23B
2023 Other Products, Total Other product sales 859M
Gilead Sciences

πŸ’° Explore more revenue segmentation data for Gilead Sciences!

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

© 2024 - 2025 InsightfulValue.com. All rights reserved. Newsletter
Legal